论文部分内容阅读
目的分析替莫唑胺口服同步全脑放疗治疗颅内转移瘤的临床疗效。方法选取2009年3月至2012年12月间入本院进行治疗的脑转移瘤患者80例为研究对象进行回顾性分析,分为对照组和研究组,对照组行单纯全脑放疗治疗,研究组行替莫唑胺口服同步全脑放疗治疗,对比两组患者近期疗效和不良反应发生情况。结果治疗组总缓解率77.5%远远高于对照组42.5%,差异具有统计学意义(P<0.05);两组不良反应主要以恶心、呕吐、骨髓抑制和白细胞降低为主,发生几率对比差异无统计学意义(P>0.05)。结论替莫唑胺口服同步全脑放疗治疗颅内转移瘤临床效果较好,安全性高,能够有效提升患者远期生存率,应用价值高。
Objective To analyze the clinical efficacy of temozolomide oral synchronous whole brain radiotherapy for intracranial metastases. Methods Eighty patients with brain metastases admitted to our hospital from March 2009 to December 2012 were retrospectively analyzed and divided into control group and study group. The control group received simple whole-brain radiotherapy. Group temozolomide oral simultaneous whole brain radiotherapy, compared the two groups of patients with short-term efficacy and adverse reactions. Results The total response rate of the treatment group was 77.5%, which was significantly higher than that of the control group (42.5%) (P <0.05). The main adverse reactions were nausea, vomiting, myelosuppression and leukopenia in the two groups, No statistical significance (P> 0.05). Conclusion Temozolomide oral total brain radiation therapy for intracranial metastases has a good clinical effect and high safety, which can effectively improve the long-term survival rate of patients with high application value.